Approval ProbabilityThere is a low probability of approval for both CB-010 at 30% and CB-011 at 20%, raising concerns over the success rate of upcoming clinical trials.
Clinical RisksRisks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and failure to achieve favorable clinical results with other pipeline candidates.
Pipeline RisksThe discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research reduces the value from the pipeline, impacting the company's long-term growth prospects.